GlobeNewsWire
27 Oct 2025, 11:00 UTC · 47w ago
Verdict
Headline takes no side. We score NMRA +0.60 across three claims — strongly bullish.
+0.60strongly bullish
More positive than 73% of ticker scores this week
What the story claims
3 claims · scored −1 bearish … +1 bullish
Neumora Therapeutics has initiated a Phase 1 study for NMRA-898, a second M4 muscarinic receptor positive allosteric modulator (PAM) for schizophrenia.
More positive than 77% of claims this week
Neumora expects to provide a comprehensive update on its M4 franchise by mid-2026.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
More positive than 51% of claims this week
NMRA-898 showed no convulsions in pre-clinical studies across multiple species, including rabbits.
More positive than 51% of claims this week
Which stocks this story touches
More positive than 73% of ticker scores this week
The company announced the initiation of a Phase 1 clinical study for NMRA-898, expanding its clinical pipeline and strategic flexibility.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
−72.2%
Price is moving against the score
$0.7313 vs $2.63 close before publication (Oct 24) · not market-adjusted
NMRA chart →
